Lupin Launches Glucagon for Injection USP, 1mg/Vial in the United States

Global pharma major Lupin Limited (Lupin) today announced the launch of Glucagon for Injection USP, 1mg/vial packaged in an emergency kit in the United States.

Glucagon for Injection USP, 1mg/vial packaged in an emergency kit is bioequivalent to Glucagon for Injection, 1 mg/vial of Eli Lilly and Company. Glucagon is indicated for the treatment of severe hypoglycemia in pediatric and adult patients with diabetes mellitus and as a diagnostic aid for use during radiologic examinations to temporarily inhibit movement of the gastrointestinal tract in adult patients.

Glucagon for Injection USP, 1mg/vial packaged in an emergency kit had an estimated annual sale of USD 122 million in the U.S. (IQVIA MAT June 2025).

Shares of Lupin Limited was last trading in BSE at Rs. 1946.15 as compared to the previous close of Rs. 1916.75. The total number of shares traded during the day was 12829 in over 2067 trades.

The stock hit an intraday high of Rs. 1950.95 and intraday low of 1906.70. The net turnover during the day was Rs. 24787120.00.

Source : Equity Bulls

Keywords

Lupin INE326A01037 Pharmaceuticals Glucagon Injection US